Skip to main content

Advertisement

SpringerLink
Log in

Approach to the immunocompromised patient with pulmonary nodules

  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

In immunocompromised hosts, the lung is a frequent site of opportunistic infection and pulmonary nodules are a common finding. Clinicians caring for these patients have an expanded selection of options available for empiric treatment and new diagnostic tools. Increased use of prophylaxis with broad-spectrum antifungals (eg, posaconazole and voriconazole) has complicated the approach to empiric therapy. This review discusses new developments in epidemiology, diagnosis, and therapy that inform the approach to the immunocompromised patient with pulmonary nodules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Copp DH, Godwin JD, Kirby KA, Limaye AP: Clinical and radiologic factors associated with pulmonary nodule etiology in organ transplant recipients. Am J Transplant 2006, 6:2759–2764.

    Article  PubMed  CAS  Google Scholar 

  2. Demirkazik FB, Akin A, Uzun O, et al.: CT findings in immunocompromised patients with pulmonary infections. Diagn Interv Radiol 2008, 14:75–82.

    PubMed  Google Scholar 

  3. Lee P, Minai OA, Mehta AC, et al.: Pulmonary nodules in lung transplant recipients: etiology and outcome. Chest 2004, 125:165–172.

    Article  PubMed  Google Scholar 

  4. Everly MJ, Bloom RD, Tsai DE, Trofe J: Posttransplant Lymphoproliferative Disorder. Ann Pharmacother 2007, 41:1850–1858.

    Article  PubMed  Google Scholar 

  5. Gulbahce HE, Pambuccian SE, Jessurun J, et al.: Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic diagnosis on patient management and prognosis. Am J Clin Pathol 2004, 121:205–210.

    Article  PubMed  Google Scholar 

  6. Garg S, Garg MS, Basmaji N: Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature. Am J Hematol 2002, 70:241–245.

    Article  PubMed  Google Scholar 

  7. Chong S, Lee KS, Kim TS, et al.: Adenovirus pneumonia in adults: radiographic and high-resolution CT findings in five patients. AJR Am J Roentgenol 2006, 186:1288–1293.

    Article  PubMed  Google Scholar 

  8. Weinstock D, Feinstein M, Sepkowitz K, Jakubowski A: High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 2003, 31:1015–1021.

    Article  CAS  Google Scholar 

  9. Cordonnier C, Martino R, Trabasso P, et al.: Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis 2002, 38:1229–1236.

    Article  Google Scholar 

  10. Jacobson K, Garcia R, Libshitz H, et al.: Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients. Eur J Clin Microbiol Infect Dis 1998, 17:615–621.

    PubMed  CAS  Google Scholar 

  11. Griffith D, Aksamit T, Brown-Elliott B, et al.: An official ATS/IDSA Statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367–416.

    Article  PubMed  CAS  Google Scholar 

  12. Silveira FP, Husain S: Fungal infections in solid organ transplantation. Med Mycol 2007, 45:305–320.

    Article  PubMed  Google Scholar 

  13. Husain S, Alexander BD, Munoz P, et al.: Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003, 37:221–229.

    Article  PubMed  Google Scholar 

  14. Marr KA, Carter RA, Crippa F, et al.: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909–917.

    Article  PubMed  Google Scholar 

  15. Malani AN, Kauffman CA: Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007, 67:1803–1812.

    Article  PubMed  CAS  Google Scholar 

  16. Kontoyiannis D, Lionakis M, Lewis R, et al.: Zygomycosis in a tertialry-care cancer center in the era of Aspergillusactive antifungal therapy: a case-control obervational study of 27 recent cases. J Infect Dis 2005, 191:1350–1360.

    Article  PubMed  Google Scholar 

  17. Pfaller M, Pappas P, Wingard J: Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006, 43:S3–S14.

    Article  CAS  Google Scholar 

  18. Roden MM, Zaoutis TE, Buchanan WL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634–653.

    Article  PubMed  Google Scholar 

  19. Almyroudis NG, Sutton DA, Linden P, et al.: Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transpl 2006, 6:2365–2374.

    Article  CAS  Google Scholar 

  20. Castiglioni B, Sutton DA, Rinaldi MG, et al.: Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine 2002, 81:333–348.

    Article  PubMed  Google Scholar 

  21. Stelzmueller I, Lass-Floerl C, Geltner C, et al.: Zygomycosis and other rare filamentous fungal infections in solid organ transplant recipients. Transpl Int 2008, 21:534–546.

    Article  PubMed  Google Scholar 

  22. Ben-Ami R, Lewis RE, Raad II, Kontoyiannis DP: Phaeohyphomycosis at a teriary cancer center: a retrospective study of 38 cases. Paper presented at 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC; October 25–28, 2008.

  23. Fishman JA: Infection in solid-organ transplant recipients. N Engl J Med 2007, 357:2601–2614.

    Article  PubMed  CAS  Google Scholar 

  24. Nicolasora N, Malani P, Riddell J, et al.: Opportunistic infections in heart transplant patients: the role of thymoglobulin and steroid dosing. Paper presented at 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, CA; 2007.

  25. Silveira FP, Husain S, Kwak EJ, et al.: Cryptococcosis in liver and kidney transplant recipients receiving antithymocyte globulin or alemtuzumab. Transpl Infect Dis 2007, 9:22–27.

    Article  PubMed  CAS  Google Scholar 

  26. Singh N, Dromer F, Perfect JR, Lortholary O: Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008, 47:1321–1327.

    Article  PubMed  Google Scholar 

  27. Peleg AY, Husain S, Qureshi ZA, et al.: Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007, 44:1307–1314.

    Article  PubMed  Google Scholar 

  28. Marty FM, Lee SJ, Fahey MM, et al.: Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102:2768–2776.

    Article  PubMed  CAS  Google Scholar 

  29. Imhof A, Balajee SA, Fredricks DN, et al.: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743–746.

    Article  PubMed  Google Scholar 

  30. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al.: Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39:584–587.

    Article  PubMed  Google Scholar 

  31. Tong SY, Peleg AY, Yoong J, et al.: Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis 2007, 9:241–243.

    Article  PubMed  CAS  Google Scholar 

  32. van Well GT, van Groeningen I, Debets-Ossenkopp YJ, et al.: Zygomycete infection following voriconazole prophylaxis. Lancet Infect Dis 2005, 5:594.

    Article  PubMed  Google Scholar 

  33. Ambrosioni J, Bouchuiguir-Wafa K, Lew D, et al.: Emerging zygomycosis infection: Does voriconazole play a role. Paper presented at 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC; October 25–28, 2008.

  34. Ullmann AJ, Lipton JH, Vesole DH, et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335–347.

    Article  PubMed  CAS  Google Scholar 

  35. Cornely OA, Maertens J, Winston DJ, et al.: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348–359.

    Article  PubMed  CAS  Google Scholar 

  36. Verweij PE, Mellado E, Melchers WJ: Multiple-triazoleresistant aspergillosis. N Engl J Med 2007, 356:1481–1484.

    Article  PubMed  CAS  Google Scholar 

  37. Bochud PY, Chien JW, Marr KA, et al.: Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008, 359:1766–1777.

    Article  PubMed  CAS  Google Scholar 

  38. Bosselmann S, Williams RO, Wiederhold NP, Frei CR: Regional and seasonal variations in invasive aspergillosis in the United States over the last decade. Paper presented at 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington DC; October 25–28, 2008.

  39. Caillot D, Couaillier JF, Bernard A, et al.: Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001, 19:253–259.

    PubMed  CAS  Google Scholar 

  40. Greene RE, Schlamm HT, Oestmann JW, et al.: Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007, 44:373–379.

    Article  PubMed  Google Scholar 

  41. Bruno C, Minniti S, Vassanelli A, Pozzi-Mucelli R: Comparison of CT features of Aspergillus and bacterial pneumonia in severely neutropenic patients. J Thorac Imaging 2007, 22:160–165.

    Article  PubMed  Google Scholar 

  42. De Pauw B, Walsh TJ, Donnelly JP, et al.: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813–1821.

    Article  PubMed  Google Scholar 

  43. Chamilos G, Lewis RE, Kontoyiannis DP: Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008, 47:503–509.

    Article  PubMed  Google Scholar 

  44. Meersseman W, Lagrou K, Maertens J, et al.: Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008, 177:27–34.

    Article  PubMed  Google Scholar 

  45. Meersseman W, Vandecasteele SJ, Wilmer A, et al.: Invasive Aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004, 170:621–625.

    Article  PubMed  Google Scholar 

  46. Minari A, Husni R, Avery RK, et al.: The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002, 4:195–200.

    PubMed  CAS  Google Scholar 

  47. Escuissato DL, Gasparetto EL, Marchiori E, et al.: Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients. AJR Am J Roentgenol 2005, 185:608–615.

    PubMed  Google Scholar 

  48. Chamilos G, Marom EM, Lewis RE, et al.: Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005, 41:60–66.

    Article  PubMed  Google Scholar 

  49. Dunagan DP, Baker AM, Hurd DD, Haponik EF: Bronchoscopic evaluation of pulmonary infiltrates following bone marrow transplantation. Chest 1997, 111:135–141.

    Article  PubMed  CAS  Google Scholar 

  50. Feinstein MB, Mokhtari M, Ferreiro R, et al.: Fiberoptic bronchoscopy in allogeneic bone marrow transplantation: findings in the era of serum cytomegalovirus antigen surveillance. Chest 2001, 120:1094–1100.

    Article  PubMed  CAS  Google Scholar 

  51. Hummel M, Rudert S, Hof H, et al.: Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates. Ann Hematol 2008, 87:291–297.

    Article  PubMed  Google Scholar 

  52. Joos L, Chajed PN, Wallner J, et al.: Pulmonary infections diagnosed by BAL: a 12-year experience in 1066 immunocompromised patients. Respir Med 2007, 101:93–97.

    Article  PubMed  Google Scholar 

  53. Maslak J, Kaul DR, Connelly J, et al.: Impact of broncho-alveolar lavage on the diagnosis and management of pulmonary complications post transplant. Paper presented at BMT Tandem Meetings. San Diego, CA; February 13–17, 2008.

  54. White P, Bonacum JT, Miller CB: Utility of fiberoptic bronchoscopy in bone marrow transplant patients. Bone Marrow Transpl 1997, 20:681–687.

    Article  CAS  Google Scholar 

  55. Lass-Florl C, Resch G, Nachbaur D, et al.: The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007, 45:e101–104.

    Article  PubMed  Google Scholar 

  56. Nosari A, Anghilieri M, Carrafiello G, et al.: Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. Haematologica 2003, 88:1405–1409.

    PubMed  Google Scholar 

  57. Jantunen E, Piilonen A, Volin L, et al.: Radiologically guided fine needle lung biopsies in the evaluation of focal pulmonary lesions in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2002, 29:353–356.

    Article  PubMed  CAS  Google Scholar 

  58. Kim K, Lee MH, Kim J, et al.: Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Am J Hematol 2002, 71:75–79.

    Article  PubMed  Google Scholar 

  59. Yeghen T, Kibbler CC, Prentice HG, et al.: Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000, 31:859–868.

    Article  PubMed  CAS  Google Scholar 

  60. Levy H, Horak DA, Tegtmeier BR, et al.: The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis. Respir Med 1992, 86:243–248.

    Article  PubMed  CAS  Google Scholar 

  61. Kedzierska A, Kochan P, Pietrzyk A, Kedzierska J: Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1→3)-beta-d-glucan antigens. Eur J Clin Microbiol Infect Dis 2007, 26:755–766.

    Article  PubMed  CAS  Google Scholar 

  62. Herbrecht R, Letscher-Bru V, Oprea C, et al.: Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002, 20:1898–1906.

    Article  PubMed  Google Scholar 

  63. Pinel C, Fricker-Hidalgo H, Lebeau B, et al.: Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003, 41:2184–2186.

    Article  PubMed  CAS  Google Scholar 

  64. Francesconi A, Kasai M, Petraitiene R, et al.: Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol 2006, 44:2475–2480.

    Article  PubMed  CAS  Google Scholar 

  65. Marr KA, Balajee SA, McLaughlin L, et al.: Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004, 190:641–649.

    Article  PubMed  CAS  Google Scholar 

  66. Shao PL, Huang LM, Hsueh PR: Invasive fungal infection—laboratory diagnosis and antifungal treatment. J Microbiol Immunol Infect 2006, 39:178–188.

    PubMed  CAS  Google Scholar 

  67. Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al.: Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003, 121:448–457.

    Article  PubMed  CAS  Google Scholar 

  68. Buchheidt D, Baust C, Skladny H, et al.: Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol 2002, 116:803–811.

    Article  PubMed  CAS  Google Scholar 

  69. Clancy CJ, Jaber RA, Leather HL, et al.: Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007, 45:1759–1765.

    Article  PubMed  CAS  Google Scholar 

  70. Husain S, Clancy CJ, Nguyen MH, et al.: Performance characteristics of the Platelia(R) Aspergillus EIA for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol 2008 (in press).

  71. Husain S, Paterson DL, Studer SM, et al.: Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007, 83:1330–1336.

    Article  PubMed  CAS  Google Scholar 

  72. Kovalevskaya E, Hummel M, Spiess B, Buchheidt D: Investigating non-blood specimens of neutropenic patients with hematological malignancies with a nested aspergillus PCR assay: clinical results. Paper presented at 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington; DC; October 25–28, 2008.

  73. Musher B, Fredricks D, Leisenring W, et al.: Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004, 42:5517–5522.

    Article  PubMed  CAS  Google Scholar 

  74. Sanguinetti M, Posteraro B, Pagano L, et al.: Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2003, 41:3922–3925.

    Article  PubMed  CAS  Google Scholar 

  75. Kakkar F, Gharabaghi F, Richardson SE: Utility of a panfungal PCR for identification of fungi from fresh and fixed tissue. Paper presented at 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC; October 25–28, 2008.

  76. Nivoix Y, Velten M, Letscher-Bru V, et al.: Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008, 47:1176.

    Article  PubMed  Google Scholar 

  77. Mellado E, Garcia-Effron G, Alcázar-Fuoli L, et al.: A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007, 51:1897–1904.

    Article  PubMed  CAS  Google Scholar 

  78. Krishanan-Natesan S, Manavathu EK, Cutright JL, et al.: In vivo efficacy of posaconazole against laboratory-selected voriconazole-resistant Aspergillus fumigatus in a neutropenic murine pulmonary aspergillosis model. Paper presented at 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC; October 25–28, 2008.

  79. Reed C, Bryant R, Ibrahim AS, et al.: Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364.

    Article  PubMed  CAS  Google Scholar 

  80. Reed C, Ibrahim A, Edwards JE, et al.: Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006, 50:3968–3969.

    Article  PubMed  Google Scholar 

  81. Spellberg B, Bonilla H, Perez M, et al.: Safety and outcomes of deferasirox iron chelation therapy for mucormycosis. Paper presented at 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC; October 25–28, 2008.

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, University of Michigan Medical School, 3120 Taubman Center, Ann Arbor, MI, 48109, USA

    Daniel R. Kaul

Authors
  1. Daniel R. Kaul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Riddell IV
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel R. Kaul.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaul, D.R., Riddell, J. Approach to the immunocompromised patient with pulmonary nodules. Curr Fungal Infect Rep 3, 45–54 (2009). https://doi.org/10.1007/s12281-009-0007-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12281-009-0007-9

Keywords

Search

Navigation